Actively Recruiting
Phase IIIII Trial of Personalized Adaptive Radiotherapy Using RAPART in Adults With Locally Advanced Non-small Cell Lung Cancer
Led by Capital Medical University · Updated on 2025-12-02
911
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating Radiosensitivity-Assisted Personalized Adaptive Radiotherapy Technology RAPART in patients with locally advanced non-small cell lung cancer NSCLC that cannot be removed by surgery. This Phase IIIII randomized clinical trial aims to compare overall survival, progression-free survival, and local progression-free survival between RAPART and conventional 60 Gy radiotherapy. The study focuses on unresectable stage III NSCLC and explores how personalized radiation doses based on biomarker sensitivity may improve outcomes. The trial includes two treatment groups one receiving RAPART technology and the other receiving conventional radiotherapy with 2 Gy per fraction. RAPART combines adaptive radiotherapy ART and radiosensitivity-assisted personalized radiotherapy RAPRT over no more than 30 treatment sessions. The first stage matches conventional radiotherapy with 23 doses of 2 Gy each. After 17-19 doses, imaging is repeated to create a new adaptive plan for the second stage. RAPRT uses ERCC12 biomarkers to categorize patients into five radiosensitivity groups, each receiving a different radiation dose 74, 66, 62, 54, or 50 Gy. Participants will be monitored from randomization up to 100 months for overall survival and for three years after treatment for progression-free survival and toxic events. The study involves regular imaging and clinical assessments to track disease progression and side effects. Researchers will evaluate how personalized radiation dosing affects survival and safety compared to standard radiotherapy. The trial is sponsored by Capital Medical University and includes adults aged 18 and older with stage III unresectable NSCLC.
CONDITIONS
Brief Title
RAPART in Locally Advanced Non-small Cell Lung Cancer Patients
Research Team
F
Feng-Ming (Spring) Kong
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here